Lucid Diagnostics (NASDAQ:LUCD) Given New $7.75 Price Target at Ascendiant Capital Markets
Lucid Diagnostics (NASDAQ:LUCD – Free Report) had its price target hoisted by Ascendiant Capital Markets from $7.50 to $7.75 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Other research analysts also recently issued reports about the stock. BTIG Research set a $2.00 target […]
Lucid Diagnostics (NASDAQ:LUCD – Free Report) had its price target hoisted by Ascendiant Capital Markets from $7.50 to $7.75 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Other research analysts also recently issued reports about the stock. BTIG Research set a $2.00 target […]
